Liu, Celina S.
Herrmann, Nathan
Song, Bing Xin
Ba, Joycelyn
Gallagher, Damien
Oh, Paul I.
Marzolini, Susan
Rajji, Tarek K.
Charles, Jocelyn
Papneja, Purti
Rapoport, Mark J.
Andreazza, Ana C.
Vieira, Danielle
Kiss, Alex
Lanctôt, Krista L.
Funding for this research was provided by:
institute of neurosciences, mental health and addiction
Article History
Received: 31 August 2021
Accepted: 16 November 2021
First Online: 4 December 2021
Declarations
:
: Ethics approval for this trial (protocol version 1.3, July 31, 2020) was obtained from Sunnybrook’s REB (075-2018) and University Health Network REB (18-5508). These research ethics boards will approve all subsequent amendments to the protocol. If participants did not have the cognitive capacity to consent, their appointed powers of attorney provide written informed consent before their participation in the trial. Participants will be informed of any changes or new information that may affect their safety and willingness to continue participating in the study.
: Not applicable.
: A list of investigators with competing interests and the details they have declared is as follows: KLL has received research grants from the National Institutes of Aging, Alzheimer’s Drug Discovery Foundation, the Alzheimer Society of Canada, Alzheimer’s Association, Canadian Institutes of Health Research, Weston Brain Institute; honoraria from BioXcel, Cerevel, Eisai and Praxis. This research is supported by the Canadian Institutes of Health Research Priority Announcement for Neurosciences, Mental Health and Addiction.NH has received peer-reviewed research grants from the Alzheimer Drug Discovery Foundation, the Alzheimer Society of Canada, the National Institute of Health, Canadian Institutes of Health Research.The remaining authors have no competing interests to declare.